Healthcare provider profile · identity verified

Rita Mathur, MD

Internal Medicine · NOTTINGHAM, MD · NPI 1619076338

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	883	289
Losartan Potassium	Losartan Potassium	482	151
Amlodipine Besylate	Amlodipine Besylate	477	162
Lisinopril	Lisinopril	374	120
Pantoprazole Sodium	Pantoprazole Sodium	331	115
Levothyroxine Sodium	Levothyroxine Sodium	325	94
Gabapentin	Gabapentin	313	106
Albuterol Sulfate Hfa	Albuterol Sulfate	300	99
Metformin Hcl	Metformin Hcl	280	94
Glipizide	Glipizide	195	69
Metoprolol Tartrate	Metoprolol Tartrate	191	64
Arexvy	Rsvpref3 Antigen/As01e/Pf	163	163
Atenolol	Atenolol	159	50
Meloxicam	Meloxicam	130	45
Hydrochlorothiazide	Hydrochlorothiazide	128	43
Furosemide	Furosemide	120	47
Tamsulosin Hcl	Tamsulosin Hcl	120	43
Famotidine	Famotidine	119	47
Pradaxa	Dabigatran Etexilate Mesylate	109	38
Wixela Inhub	Fluticasone Propion/Salmeterol	108	33
Trazodone Hcl	Trazodone Hcl	105	35
Simvastatin	Simvastatin	101	28
Pravastatin Sodium	Pravastatin Sodium	91	29
Sertraline Hcl	Sertraline Hcl	83	26
Pregabalin	Pregabalin	80	19
Escitalopram Oxalate	Escitalopram Oxalate	78	33
Metoprolol Succinate	Metoprolol Succinate	76	25
Hydralazine Hcl	Hydralazine Hcl	74	23
Tramadol Hcl	Tramadol Hcl	67	15
Humulin N Kwikpen	Insulin Nph Human Isophane	66	18
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	suppressed
Montelukast Sodium	Montelukast Sodium	59	21
Allopurinol	Allopurinol	58	21
Metformin Hcl Er	Metformin Hcl	58	20
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	58	23
Pioglitazone Hcl	Pioglitazone Hcl	57	17
Prednisone	Prednisone	56	47
Oxycodone Hcl	Oxycodone Hcl	54	suppressed
Clopidogrel	Clopidogrel Bisulfate	51	18
Humulin N	Insulin Nph Human Isophane	51	14
Ozempic	Semaglutide	51	suppressed
Citalopram Hbr	Citalopram Hydrobromide	50	15
Nifedipine Er	Nifedipine	49	13
Warfarin Sodium	Warfarin Sodium	49	14
Bupropion Xl	Bupropion Hcl	47	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	13
Rosuvastatin Calcium	Rosuvastatin Calcium	46	14
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	45	20
Zolpidem Tartrate	Zolpidem Tartrate	45	suppressed
Alvesco	Ciclesonide	42	15
Jardiance	Empagliflozin	42	22
Carvedilol	Carvedilol	41	15
Ibuprofen	Ibuprofen	41	13
Alendronate Sodium	Alendronate Sodium	39	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	37	31
Spiriva Respimat	Tiotropium Bromide	37	11
Humalog Kwikpen U-100	Insulin Lispro	36	11
Omeprazole	Omeprazole	36	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	36	suppressed
Lovastatin	Lovastatin	34	11
Potassium Chloride	Potassium Chloride	34	12
Spironolactone	Spironolactone	34	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	34	18
Doxycycline Monohydrate	Doxycycline Monohydrate	33	30
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	31	suppressed
Nabumetone	Nabumetone	30	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	29	11
Mirtazapine	Mirtazapine	28	14
Duloxetine Hcl	Duloxetine Hcl	27	14
Insulin Syringe	Syringe And Needle,insulin,1ml	26	11
Primidone	Primidone	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Xarelto	Rivaroxaban	23	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	19	suppressed
Torsemide	Torsemide	19	suppressed
Eliquis	Apixaban	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Calcitriol	Calcitriol	13	suppressed
Cefdinir	Cefdinir	13	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Temazepam	Temazepam	13	suppressed
Zonisamide	Zonisamide	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Finasteride	Finasteride	11	suppressed
Fluocinonide	Fluocinonide	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Nystatin	Nystatin	11	suppressed
Sucralfate	Sucralfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error